ScholarIQanswers from OpenAlex & ORCID
Jason Gotlib
ResearcherPublications, citations & collaboration network
Jason Gotlib is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jason Gotlib have?
ScholarIQindexed works
Jason Gotlib has 695 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jason Gotlib have?
ScholarIQcitation count
Jason Gotlib has 32,249 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jason Gotlib?
ScholarIQh-index
Jason Gotlib has an h-index of 84 in OpenAlex.
What is the i10-index of Jason Gotlib?
ScholarIQi10-index
Jason Gotlib has an i10-index of 271 in OpenAlex.
What is the ORCID of Jason Gotlib?
ScholarIQorcid
The ORCID for Jason Gotlib is on the source record.
What is the OpenAlex record for Jason Gotlib?
ScholarIQopenalex
The OpenAlex for Jason Gotlib is on the source record.
What are the most-cited papers on Jason Gotlib?
ScholarIQmost cited works
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, Timothy Devos, Miklós Egyed, Andrzei Hellmann, Donal P. McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason Gotlib
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, R. S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, E. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, V. Sandor, Hagop M. Kantarjian, For the COMFORT-I investigators
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Jerald P. Radich, Michael W. Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori J. Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal M. Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra Sweet, Moshe Talpaz, James E. Thompson, David T. Yang, Kristina M. Gregory, Hema Sundar
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori J. Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian G. Oehler, Arnel Pallera, Mrinal M. Patnaik, Keith W. Pratz, Iskra Pusic, Michal G. Rose, B. Douglas Smith, David S. Snyder, Kendra Sweet, Moshe Talpaz, James E. Thompson, David T. Yang, Kristina M. Gregory, Hema Sundar
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian, Jason Gotlib, F. Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, V. Sandor, P. Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srđan Verstovšek, on behalf of the COMFORT Investigators